TFX Teleflex Incorporated

Teleflex Incorporated Announces Worldwide Voluntary Recall of COMFORT FLO® Humidification System

Teleflex Incorporated Announces Worldwide Voluntary Recall of COMFORT FLO® Humidification System

WAYNE, Pa., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies for critical care and surgery, has announced a worldwide voluntary recall of the COMFORT FLO® Humidification System.  The recalled products provide a continuous flow of heated and humidified gas to COMFORT FLO® patients in professional health care environments. The products involved in the recall are as follows:

Product NameProduct CodeLot Numbers
COMFORT FLO Humidification System2410See Appendix 1
COMFORT FLO Humidification System with Remote Port Extension2414
Corrugated COMFORT FLO2415
Corrugated COMFORT FLO Remote Temp Port2416

These recalled products were manufactured from October 2014 through June 2019. Products manufactured after June 2019 are now being packaged with our new COMFORT FLO® columns for high flow therapy. The recalled product can be identified by the presence of only one white reservoir clamp on the feed tube (distinguishing itself from new product which contains two blue reservoir clamps on the feed tube).  Specific lot codes may be found through the following link:

Teleflex is recalling the above product codes and lots due to the potential for water to flood the column and enter the circuit under circumstances where an abnormal pressure differential is created between the water bottle and the column during high flow oxygen therapy.

The potential health consequence of exposure to water ingress is the aspiration of fluid into the nose and lungs that may result in oxygen desaturation. The company has received 102 complaints of water ingress in which intervention has been required on several patients to prevent serious injury or permanent impairment.  The Company has not received any reports of death. In one instance, fluid aspiration and subsequent desaturation required invasive respiratory support including intubation and positive pressure ventilation. In another instance, an infant in a NICU experienced aspiration with desaturation and bradycardia requiring bag mask ventilation. Aspiration in patients requiring supplementary oxygen to prevent hypoxemia also has the potential to result in respiratory arrest, cardiac arrest, permanent brain and/or cardiac injury, and death. The long-range health consequences depend on the degree and duration of desaturation and the rapidity and success of medical interventions to resuscitate the patient.

The U.S. Food and Drug Administration (FDA) has classified the recall of the COMFORT FLO® Humidification System as a Class I recall.  FDA defines a Class I recall as, “a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”

Consumers who have affected product should immediately identify all patients that are currently exposed to use of this product, discontinue use, and return all affected product to Teleflex. The recall notice, with a list of affected product codes and lot numbers, can be found through the following link:

Consumers with questions may contact the company at 1-866-396-2111; 8am to 7pm, ET, Monday through Friday or email .

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.  Complete and submit the report Online: , or via Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2020 Teleflex Incorporated. All rights reserved. MC-XXXXXX

Source:

Teleflex Incorporated

Jake Elguicze

Treasurer and Vice President, Investor Relations

610-948-2836

EN
14/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhex...

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guin...

 PRESS RELEASE

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Thro...

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and th...

 PRESS RELEASE

Teleflex Publishes 2024 Global Impact Report

Teleflex Publishes 2024 Global Impact Report Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Cl...

 PRESS RELEASE

Teleflex Showcases New Clinical Data Presented at the 2025 American Ur...

Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 ...

 PRESS RELEASE

New Retrospective Study Reports Significantly Reduced Post-Operative G...

New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading g...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch